caa a22 4500 465785964 CHVBK 20180323112009.0 cr unu---uuuuu 170327e19900401xx s 000 0 eng 10.1007/BF00842796 doi (NATIONALLICENCE)springer-10.1007/BF00842796 Britton Keith Physician in Charge, Department of Nuclear Medicine, St. Bartholomew's Hospital, EC1A 7BE, West Smithfield, London, UK aut The development of new radiopharmaceuticals [Elektronische Daten] [Keith Britton] The development of new radiopharmaceuticals is the basis of the continuing growth of nuclear medicine. Chemical interactions of electron clouds in their three dimensional conformations bring together, in the process of molecular recognition, the reaction of antibody and antigen, receptor and ligand, enzyme and substrate, hormone and response site. This convergence enables the computer design of molecules such as ligands to fit computer-displayed conformational models showing active centres, positive and negative charges and other interactions. Indeed, given a particular molecule, a complementary binding structure can be devised. The hybridoma approach to monoclonal antibody production is being superceded by the bacterial bioengineer. The gene for the hypervariable region from the spleen cells of immunized mouse can be coupled with the myeloma gene. The polymerase chain reaction can duplicate the DNA a million times over in 20 min and the result transfected into a bacterial plasmid to produce the antibody. These scientific problems are soluble in principle and are being solved. However, so much damage to this developing biological field is being done by regulatory authorities that one must ask who should or can regulate the regulators. These problems have to be overcome in order to provide the new radiopharmaceuticals that are the food and wine of nuclear medicine. Springer-Verlag, 1990 Radiopharmaceuticals nationallicence Molecular recognition nationallicence Genetic engineering nationallicence Heart nationallicence Monoclonal antibody nationallicence European Journal of Nuclear Medicine Springer-Verlag 16/4-6(1990-04-01), 373-385 0340-6997 16:4-6<373 1990 16 259 https://doi.org/10.1007/BF00842796 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00842796 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Britton Keith Physician in Charge, Department of Nuclear Medicine, St. Bartholomew's Hospital, EC1A 7BE, West Smithfield, London, UK aut NATIONALLICENCE 773 0- European Journal of Nuclear Medicine Springer-Verlag 16/4-6(1990-04-01), 373-385 0340-6997 16:4-6<373 1990 16 259 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer